COVID-۱۹ and its Outcomes in Multiple Sclerosis Patients
عنوان مقاله: COVID-۱۹ and its Outcomes in Multiple Sclerosis Patients
شناسه ملی مقاله: JR_CJNS-8-2_004
منتشر شده در در سال 1401
شناسه ملی مقاله: JR_CJNS-8-2_004
منتشر شده در در سال 1401
مشخصات نویسندگان مقاله:
Masood Najafi - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Sharareh Eskandarieh - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Nasim Rezaeemanesh - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Hora Heydari - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Marzieh Moosavi - Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Hossein Harirchian - Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
خلاصه مقاله:
Masood Najafi - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Sharareh Eskandarieh - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Nasim Rezaeemanesh - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Hora Heydari - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Marzieh Moosavi - Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Hossein Harirchian - Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Background: Coronavirus Disease ۲۰۱۹ (COVID-۱۹) is a highly contagious disease that
resulted in ۴۵۳۳۶۴۵ deaths until September first, ۲۰۲۱. Multiple Sclerosis (MS) patients receive
immunosuppressive drugs. Thus, there is a concern that these drugs will reduce the patient’s
immune system resistance against COVID۱۹.
Objectives: This study aimed to evaluate the epidemiology of COVID۱۹ and its impact on MS
patients in our university hospital in Tehran City, Iran.
Materials & Methods: A cross-sectional study was conducted based on hospital-based registry
data from May ۲۰۲۰ to March ۲۰۲۱. Among more than ۵۰۰ registered MS patients in Imam
Khomeini Hospital in Tehran City, Iran, referring within our study period, ۸۴ patients reported
SARS-COV۲ infection. The diagnosis of MS was confirmed by the McDonald criteria. Moreover,
the diagnosis of COVID-۱۹ in MS patients was established by the real-time-PCR technique and
chest computed tomography.
Results: Out of ۸۴ MS patients with SARS-COV۲ infection, ۵۵(۶۵.۵%) were women, and their
mean age was ۳۷.۴۸ years. The most commonly used medications by MS patients were Rituximab
۲۰ (۲۶.۳%) and Dimethyl Fumarate ۱۴(۱۸.۴%). Totally, ۹(۱۰.۸%) of the patients needed to be
hospitalized due to COVID-۱۹, with a mean hospitalization duration of ۵.۸۸ days. A total of ۱
(۱.۲%) death was reported.
Conclusion: Compared to the healthy population, COVID-۱۹ is not more serious in MS patients.
Most MS patients with COVID-۱۹ infection were not hospitalized and continued their medication
during the infection.
کلمات کلیدی: Multiple Sclerosis (MS), Coronavirus Disease ۲۰۱۹ (COVID-۱۹), Epidemiology
صفحه اختصاصی مقاله و دریافت فایل کامل: https://civilica.com/doc/1429040/